This case study by 2010 AVAC Advocacy Fellow Richard Hasunira assesses the community engagement efforts of the Masaka trial site through interviews with participants, trial staff, and other stakeholders. It highlights success that other trials should replicate and lessons learned from shortcomings.
Community Involvement in HIV Prevention Research: Experiences and perceptions of communities participating in the MDP 301 microbicide trial in Masaka, Uganda
MUWRP/AVAC: Biomedical HIV Prevention Research Stakeholder Training Resource
This manual, developed by 2010 AVAC Advocacy Fellow Jauhara Nanyondo, is an HIV prevention literacy tool intended to improve reporting by Ugandan media. It covers background information on HIV, provides an overview of existing and emerging prevention options, and discusses clinical research process and ethics.
2005 AVAC Report: AIDS Vaccines at the Crossroads
This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.
2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order
This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.
From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2013 report finds that the US government was again the biggest contributor and calls for other countries and sectors to step up to end a seven-year trend of flat funding. It also profiles growing interest in research on a therapeutic vaccines.
Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research & Development
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2012 report finds increased investment by private foundations was unable to make up for the effects of the economic downturn. It also highlights the contributions to prevention research of trial participants.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
2013 AVAC Report: Research and Reality
Research & Reality calls on funders and researchers to capitalize on lessons learned from a range of recent HIV prevention trials via better problem solving, more critical thinking and coordinated action. This year’s AVAC Report identifies progress and gaps in large-scale human trials, rollout of proven options and ongoing research for new advances that women and men will want to use.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials, second edition
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV prevention trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
2012 AVAC Report: Achieving the End—One Year and Counting
AVAC Report 2012, Achieving the End—One Year and Counting, sets a clock on the global drive to end the AIDS epidemic. The past twelve months have seen remarkable global consensus that it is possible to begin to end the epidemic. The same time period has seen concepts like “combination prevention” and “treatment as prevention” capture the world’s attention. But without specific interim goals—and far more precision about what combination prevention and other key concepts mean—the lofty goal of ending the epidemic will not be achieved.